EGFR and non-small cell lung carcinoma: Targeted medicines can significantly prolong survival, such as EGFR-targeting TKIs in EGFR mutant NSCLCs and crizotinib (a dual ALK/MET TKI) in ALK-positive NSCLC patients (Kwak et al., 2010; Camidge et al., 2011; Sebastian et al., 2014).